Substituted heteroaromatic compounds: effect on nicotine self-administration in rats

Abstract

The results indicate that chemical analogs of nicotine can play a role in nicotine self-administration harm reduction but a non-nAChR and a non-hDAT mechanism are likely involved.

Development of Novel Pharmacotherapeutics for Tobacco Dependence: Progress and Future Directions

“…In this review, we have recommended some guidelines that may serve to facilitate the identification of already approved drugs for repurposing as smoking-cessation agents. Specifically, three key characteristics of already approved molecules are particularly attractive when considering which may be suitable for clinical assessment: Those molecules that are known to be safe in human with minimal toxicity issues and favorable safety and tolerability profiles; those that modulate the activity of targets expressed in brain circuits known to control the reinforcing properties of nicotine, such as the mesoaccumbens dopamine system, the habenulo-interpeduncular system, and the insular cortex; and finally, those molecules that modulate the activity of targets for Levin et al, 2010) SB-334867 Hypocretin-1 (orexin-1) receptor antagonist (Hollander et al, 2008;Lesage, Perry, Kotz, Shelley, & Corrigall, 2010;Plaza-Zabala et al, 2010) Various substituted heteroaromatic compounds hCYP-2A6 inhibitors (Cashman et al, 2012) VDM11 Anandamide transport inhibitor (Gamaleddin, Guranda, Goldberg, & Le Foll, 2011) which there is evidence to support a role in tobacco dependence, for example, human genetics evidence or anecdotal reports of decreases in smoking behavior.…”